# AZD1152 in Patients With Advanced Solid Malignancies-Study 1

> **NCT00497731** · PHASE1 · TERMINATED · sponsor: **AstraZeneca** · enrollment: 70 (estimated)

## Conditions studied

- Solid Tumors

## Interventions

- **DRUG:** AZD1152

## Key facts

- **NCT ID:** NCT00497731
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-05
- **Primary completion:** 2008-06
- **Final completion:** 2009-04
- **Target enrollment:** 70 (ESTIMATED)
- **Why stopped:** Efficacy seen in the solid tumour patient population was not sufficient to continue research with AZD1152 monotherapy in solid tumors at that time.
- **Last updated:** 2009-06-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00497731

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00497731, "AZD1152 in Patients With Advanced Solid Malignancies-Study 1". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00497731. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*